N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability

2006 ◽  
Vol 44 (1) ◽  
Author(s):  
Stefanie Albers ◽  
Thomas S. Mir ◽  
Munif Haddad ◽  
Stephanie Läer
Keyword(s):  
Heart Disease ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Pediatric Patients ◽  
Pediatric Population ◽  
Method Comparison ◽  
Normal Ranges ◽  
Interlaboratory Variability ◽  
Percentile Curve

AbstractThe aim of the present study was the investigation of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the pediatric population. This is essential for adequate monitoring and classification of pediatric patients with heart disease, but no consistent data are available yet. In addition, the comparability of two commercially available NT-proBNP assays and the inter-laboratory variability for the most suitable one were assessed. For this purpose, 408 subjects (1–29years) were included. NT-proBNP was determined with a non-competitive electrochemiluminescent immunoassay (Roche NT-proBNP; n=402) and a competitive enzyme-immunoassay (Biomedica NT-proBNP; n=402). Inter-laboratory variability was evaluated for the Roche assay by stepwise inclusion of four and 11 centers throughout Germany, respectively. Roche NT-proBNP ranged from 5.0 to 391.5ng/L, with higher values for younger children. The 97.5th (75th) percentile curve ranged from 319.9ng/L (231.2 ng/L, 1–3years) to 114.9ng/L (53.3 ng/L, 18years). In contrast, Biomedica NT-proBNP ranged from 253.7 to 7602.8 ng/L, with no significant age dependency. The mean difference between the assays was 1649.7ng/L (95% confidence interval 1546.3–1753.1ng/L). Inter-laboratory variability ranged from 6.5% to 3.8%, covering a range from 51.3 to 6618.1ng/L. The assay seems to influence the interpretation of resulting NT-proBNP values and therefore has to be chosen carefully. For the monitoring and classification of pediatric patients with congenital heart disease, age-based NT-proBNP values should be used.

scholarly journals Pro-brain natriuretic peptide predicts severe cardiovasclar events in patients with heart disease

2003 ◽  
Vol 41 (6) ◽  
pp. 278
Author(s):  
Thomas Weber ◽  
Johann Auer ◽  
Elisabeth Lassnig ◽  
Martina Strobl ◽  
Robert Berent ◽  
...  
Keyword(s):  
Heart Disease ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide

scholarly journals Efficacy and Safety of TCMI in Patients With Combined Coronary Heart Disease and Heart Failure: A Systematic Review and Network Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Penglu Wei ◽  
Kuo Yang ◽  
Dehuai Long ◽  
Yupei Tan ◽  
Wenlong Xing ◽  
...  
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Effectiveness Rate

Objective: To compare the efficacy and safety of conventional treatments (CTs) to those that included traditional Chinese medicine injections (TCMIs) in patients with combined coronary heart disease and heart failure (CHD-HF).Methods: Eight electronic literature databases (PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, China National Knowledge Infrastructure Database, Chinese Scientific Journal Database, Wanfang Database, Chinese Biomedical Database) were searched from their inceptions to May 18, 2021, to identify relevant randomised controlled trials (RCTs). The primary outcomes analyzed included the total effectiveness rate and adverse events (ADRs). The secondary outcomes analyzed included the left ventricular ejection fraction (LVEF), N-terminal pro-brain natriuretic peptide (NT-proBNP), brain natriuretic peptide (BNP), and 6-min walk test (6MWT). Cochrane risk-of-bias tool was used to assess quality of the analyzed RCTs. Stata and OpenBUGS software were used to prior to the systematic review and network meta-analysis.Results: Sixty-one eligible trials involved 5,567 patients and one of the following 15 TCMIs: Shuxuetong, Shenmai, Shenfu, Shengmai, Danshenduofenyansuan, Danhong, Dazhuhongjingtian, Xinmailong, Dengzhanxixin, Gualoupi, Shuxuening, Xuesaitong, Yiqi Fumai, Shenqi Fuzheng, Huangqi. Network meta-analysis revealed that Shuxuetong injection + CT group was superior to CT only in improving the total effectiveness rate [odds ratio (OR): 7.8, 95% confidence interval (CI): 1.17–27.41]. Shenmai injection + CT was superior to CT only for LVEF (OR: 8.97, CI: 4.67–13.18), Xinmailong injection + CT was superior to CT only for NT-proBNP (OR: −317.70, CI: −331.10–303.10), Shenqi Fuzheng injection + CT was superior to CT only for BNP (OR: −257.30, CI: −308.40–242.80); and Danhong injection + CT was superior to CT only for 6MWT (OR: 84.40, CI: 62.62−106.20). Different TCMIs had different toxicity spectrums.Conclusion: TCMIs combined with CT are better than CT alone in treating CHD-HF. Different TCMIs improve different outcomes. Additional properly designed RCTs are needed to conduce a more refined comparison of various TCMIs.Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42021258263].

Brain natriuretic peptide: the reason of respiratory distress is heart disease or lung disease?

2015 ◽  
Vol 33 (5) ◽  
pp. 697-700 ◽  
Author(s):  
Taylan Sahingozlu ◽  
Ulaş Karadas ◽  
Kayi Eliacik ◽  
Ali Rahmi Bakiler ◽  
Nihal Ozdemir Karadas ◽  
...  
Keyword(s):  
Heart Disease ◽  
Respiratory Distress ◽  
Brain Natriuretic Peptide ◽  
Lung Disease ◽  
Natriuretic Peptide

scholarly journals Brain natriuretic peptide in pregnant women with heart disease

2019 ◽  
Vol 13 (1) ◽  
pp. 25-29
Author(s):  
Karanvir Singh ◽  
Pooja Sikka ◽  
Vanita Suri ◽  
Rishikesh Prasad ◽  
Madhu Khullar ◽  
...  
Keyword(s):  
Heart Failure ◽  
Adverse Event ◽  
Heart Disease ◽  
Adverse Events ◽  
Brain Natriuretic Peptide ◽  
Pregnant Women ◽  
Natriuretic Peptide ◽  
Cardiac Events ◽  
Plasma Brain Natriuretic Peptide ◽  
Rheumatic Heart

Background Plasma brain natriuretic peptide levels were prospectively studied in pregnant women with heart disease. Methods Fifty pregnant women with heart disease and 25 controls were evaluated at 24 weeks or under, 30–32 weeks, 34 weeks or more of gestation, and 6 weeks postpartum. Adverse maternal cardiac events were hospitalization for worsening heart failure, stroke, and death. Results Thirty-eight (76%) women had rheumatic heart disease. Plasma brain natriuretic peptide levels were (in cases and controls) 118.3 ± 46.5 pg/ml and 66.3 ± 15.9 pg/ml (at 24 weeks or under), 124.8 ± 30.4 pg/ml and 68.4 ± 16.5 pg/ml (30–32 weeks), 135.8 ± 34.9 pg/ml and 68.6 ± 15.6 pg/ml (34 weeks or more), and 110.1 ± 21.9 pg/ml and 65.0 ± 16.1 pg/ml (6 weeks postpartum) (p = .0001). Eighteen women had adverse events. Of these, only 1 had a level less than 100 pg/ml, 12 were between 100 and 200 pg/ml, and 5 more than 200 pg/ml. Conclusions Plasma brain natriuretic peptide levels were higher in women with heart disease at all periods of gestation as well as six weeks postpartum. No woman with a plasma brain natriuretic peptide levels of 98 pg/ml or less had an adverse event.

scholarly journals Brain natriuretic peptide is removed by continuous veno-venous hemofiltration in pediatric patients

2009 ◽  
Vol 9 (1) ◽  
pp. 33-36 ◽  
Author(s):  
Z. Ricci ◽  
C. Garisto ◽  
S. Morelli ◽  
L. Di Chiara ◽  
C. Ronco ◽  
...  
Keyword(s):  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Pediatric Patients

scholarly journals Hypermethylation of brain natriuretic peptide gene is associated with the risk of rheumatic heart disease

2017 ◽  
Vol 37 (1) ◽  
Author(s):  
Ni Li ◽  
Dawei Zheng ◽  
Lebo Sun ◽  
Huoshun Shi ◽  
Xiuying Zhu ◽  
...  
Keyword(s):  
Heart Disease ◽  
Brain Natriuretic Peptide ◽  
Rheumatic Heart Disease ◽  
Natriuretic Peptide ◽  
Anticoagulant Therapy ◽  
Significant Difference ◽  
Term Administration ◽  
Promoter Dna ◽  
Peptide Gene ◽  
Rheumatic Heart

To investigate the contribution of brain natriuretic peptide (BNP) promoter DNA methylation to the risk of rheumatic heart disease (RHD) and the influence of warfarin anticoagulant therapy on BNP methylation levels for RHD patients after surgery. BNP methylation levels were determined by bisulfite pyrosequencing from plasma samples of RHD patients compared with healthy controls. Several factors influencing the RHD patients were included like age, smoking and cholesterol levels. A fragment of five CG sites (CpG1–5) in the promoter region of BNP gene was measured. BNP gene hypermethylation was found in CpG4 and CpG5 in RHD patients compared with non-RHD controls. A significant difference was also observed between RHD patients with long-term administration of warfarin and RHD patients who had recently undergone an operation. Moreover, single CpG4 and CpG5 analysis revealed a significant increase in methylation levels in men. BNP gene body hypermethylation is associated with the risk of RHD, and also influenced by the warfarin anticoagulant therapy of RHD patients after surgery, which could represent novel and promising targets for therapeutic development.

scholarly journals Usefulness of N-Terminal-Pro-B-Type Natriuretic Peptide as a Screening Tool for Identifying Pediatric Patients With Congenital Heart Disease

2011 ◽  
Vol 42 (2) ◽  
pp. 75-80 ◽  
Author(s):  
Emmanuel Jairaj Moses ◽  
Sharifah A.I. Mokhtar ◽  
Amir Hamzah ◽  
Basir Selvam Abdullah ◽  
Narazah Mohd Yusoff
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Natriuretic Peptide ◽  
Congenital Heart ◽  
Pediatric Patients ◽  
Screening Tool
Sign in / Sign up

Export Citation Format

Share Document